New York, USA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy (DMD) Clinical Trial Analysis Featuring 60+ Companies | DelveInsight
Duchenne Muscular Dystrophy pipeline constitutes 60+ key companies continuously working towards developing 75+ Duchenne Muscular Dystrophy treatment therapies, analyzes DelveInsight
DelveInsight’s 'Duchenne Muscular Dystrophy Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline duchenne muscular dystrophy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the duchenne muscular dystrophy pipeline domain.
Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report
- DelveInsight’s duchenne muscular dystrophy pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for duchenne muscular dystrophy treatment.
- Key duchenne muscular dystrophy companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutics, and others are evaluating new drugs for duchenne muscular dystrophy to improve the treatment landscape.
- Promising duchenne muscular dystrophy pipeline therapies in various stages of development include Vamorolone, Delandistrogene moxeparvovec, Givinostat, WVE N531, Pamrevlumab, EDG 5506, Fordadistrogene movaparvovec, Renadirsen, SRP 5051, EN 001, TAS-205, SGT 001, CAP 1002, NS 089/NCNP 02, ENTR-601-44, SRP-9001, GNT 0004, SRP-5051, UX810, SGT-003, Exon 53, Exon 45, AVGN7, PGN EDO51, PGN EDODM1, PGN EDO53, PGN EDO44, PGN EDO45, ALT1102, BMN 351, AOC 1044, SRP-9001, GNT 0004, SRP-5053, SRP-5045, SRP-5052, SRP-5044, SRP-5050, SRP-5051, DYNE-251, SGT-003, RGX-202, Elamipretide, and others.
- In July 2022, Capricor Therapeutics dosed the first subject in Phase III HOPE-3 clinical trial of cell therapy, CAP-1002, to treat late-stage Duchenne muscular dystrophy (DMD).
- In June 2022, FibroGen announced that it had completed the target enrollment for its ongoing Phase III LELANTOS-2 clinical trial (NCT04632940) of pamrevlumab, a first-in-class connective tissue growth factor (CTGF) inhibitor antibody, in patients with Duchenne muscular dystrophy (DMD). The trial is set to read out topline data in the second half of 2023 after completing the target enrollment of 73 patients with Duchenne muscular dystrophy aged 6 to 12 years.
- In May 2022, Stealth BioTherapeutics announced that the FDA had granted orphan drug designation to elamipretide for the treatment of Duchenne muscular dystrophy.
- In January 2022, The US Food and Drug Administration (FDA) approved Regenxbio’s request to launch a Phase I/II clinical trial in the U.S. evaluating the safety and efficacy of RGX-202, its experimental gene therapy for Duchenne muscular dystrophy (DMD).
- In June 2020, Sarepta Therapeutics announced that they have entered into a Research License and Option agreement granting Sarepta an option to license the rights to develop and commercialize Selecta’s immune tolerance platform, ImmTOR, for use in Duchenne muscular dystrophy (DMD) and certain limb-girdle muscular dystrophies (LGMDs).
- In November 2021, CANbridge Pharmaceuticals announced that it has entered into a two-year sponsored research agreement with the University of Washington School of Medicine in Seattle, Washington, for gene therapy research in Duchenne muscular dystrophy (DMD), a rare neuromuscular disease
Request a sample and discover the recent advances in duchenne muscular dystrophy treatment drugs @Duchenne Muscular Dystrophy Pipeline Report
The duchenne muscular dystrophy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage duchenne muscular dystrophy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the duchenne muscular dystrophy clinical trial landscape.
Duchenne Muscular Dystrophy Overview
Duchenne muscular dystrophy (DMD) is one of the most severe inherited muscular dystrophies. It is the most common hereditary neuromuscular disease and has no preference for any race or ethnic group. Duchenne muscular dystrophy symptoms include atrophy of the pelvic muscles, followed by involvement of the shoulder muscles. As the condition progresses, muscle weakness and atrophy move from the trunk and forearms to other muscles throughout the body. Mutations in the DMD gene on the X chromosome are among the Duchenne muscular dystrophy causes.
Furthermore, for duchenne muscular dystrophy diagnosis, a thorough clinical assessment, a detailed patient history, and a number of specialized diagnostics, including molecular genetic tests, are used.
Find out more about duchenne muscular dystrophy treatment drugs @Drugs for Duchenne Muscular Dystrophy Treatment
A snapshot of the Duchenne Muscular Dystrophy Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Vamorolone | Santhera | Pre-registration | Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist | Oral |
| Givinostat | Italfarmaco | Phase III | Histone deacetylase inhibitor | Oral |
| Pamrevlumab | Fibrogen | Phase III | Connective tissue growth factor inhibitor | Intravenous |
| Delandistrogene moxeparvovec | Roche/Sarepta Therapeutics | Phase III | Dystrophin replacement; Gene transference | Intravenous |
| EDG 5506 | Edgewise Therapeutics | Phase II | Creatine kinase inhibitor; Myosin inhibitor | Oral |
| SRP-5051 | Sarepta Therapeutics | Phase II | Dystrophin expression modulator | Intravenous |
| WVE N531 | Wave Life Sciences Ltd | Phase I/II | Dystrophin expression stimulants; RNA interference | Intravenous |
| PGN EDO51 | PepGen | Phase I | Dystrophin expression stimulant | Intravenous |
| UX810 | Ultragenyx Pharmaceutical | Preclinical | Dystrophin replacement; Gene transference | Parenteral |
Learn more about the emerging duchenne muscular dystrophy pipeline therapies @Duchenne Muscular Dystrophy Clinical Trials
Duchenne Muscular Dystrophy Therapeutics Assessment
The duchenne muscular dystrophy pipeline report proffers an integral view of the duchenne muscular dystrophy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Duchenne Muscular Dystrophy Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intravenous, Oral, Subcutaneous
- Therapeutics Assessment By Molecule Type: Cell therapy, Peptide, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Glucocorticoid receptor agonists, Mineralocorticoid receptor antagonists, Histone deacetylase inhibitors, Connective tissue growth factor inhibitors, Dystrophin expression stimulants, RNA interference, Dystrophin replacements, Gene transference, Creatine kinase inhibitors, Myosin inhibitors, Protein synthesis modulators, Prostaglandin synthase inhibitors
- Key Duchenne Muscular Dystrophy Companies: Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutic, and others.
- Key Duchenne Muscular Dystrophy Pipeline Therapies: Vamorolone, Delandistrogene moxeparvovec, Givinostat, WVE N531, Pamrevlumab, EDG 5506, Fordadistrogene movaparvovec, Renadirsen, SRP 5051, EN 001, TAS-205, SGT 001, CAP 1002, NS 089/NCNP 02, ENTR-601-44, SRP-9001, GNT 0004, SRP-5051, UX810, SGT-003, Exon 53, Exon 45, AVGN7, PGN EDO51, PGN EDODM1, PGN EDO53, PGN EDO44, PGN EDO45, ALT1102, BMN 351, AOC 1044, SRP-9001, GNT 0004, SRP-5053, SRP-5045, SRP-5052, SRP-5044, SRP-5050, SRP-5051, DYNE-251, SGT-003, RGX-202, Elamipretide, and others.
Dive deep into rich insights for new drugs for duchenne muscular dystrophy treatment, visit @Duchenne Muscular Dystrophy Gene Therapy
Table of Contents
| 1. | Duchenne Muscular Dystrophy Pipeline Report Introduction |
| 2. | Duchenne Muscular Dystrophy Pipeline Report Executive Summary |
| 3. | Duchenne Muscular Dystrophy Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Duchenne Muscular Dystrophy Clinical Trial Therapeutics |
| 6. | Duchenne Muscular Dystrophy Pipeline: Late Stage Products (Pre-registration) |
| 6.1 | Vamorolone: Santhera |
| 7. | Duchenne Muscular Dystrophy Pipeline: Late Stage Products (Phase III) |
| 7.1 | Givinostat: Italfarmaco |
| 8. | Duchenne Muscular Dystrophy Pipeline: Mid Stage Products (Phase II) |
| 8.1 | EDG 5506: Edgewise Therapeutics |
| 9. | Duchenne Muscular Dystrophy Pipeline: Early Stage Products (Phase I) |
| 9.1 | PGN EDO51: PepGen |
| 10. | Duchenne Muscular Dystrophy Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Duchenne Muscular Dystrophy Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Duchenne Muscular Dystrophy Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the duchenne muscular dystrophy pipeline therapeutics, reach out @Duchenne Muscular Dystrophy Treatment Drugs
Related Reports
Duchenne Muscular Dystrophy Market
Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key duchenne muscular dystrophy companies including Edgewise Therapeutics, Pfizer, Daiichi Sankyo, among others.
Duchenne Muscular Dystrophy Epidemiology Forecast
Duchenne Muscular Dystrophy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted duchenne muscular dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nonsense Mutation Duchenne Muscular Dystrophy Pipeline
Nonsense Mutation Duchenne Muscular Dystrophy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonsense mutation duchenne muscular dystrophy companies, including Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, among others.
Becker Muscular Dystrophy Pipeline
Becker Muscular Dystrophy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key becker muscular dystrophy companies, including Epirium Bio, Ultragenyx, Strykagen, among others.
Facioscapulohumeral Muscular Dystrophy PIpeline
Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key facioscapulohumeral muscular dystrophy companies, including miRecule, Arrowhead Pharmaceuticals, Fulcrum Therapeutics, among others.
Other Trending Reports
Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market
For more updates on Duchenne Muscular Dystrophy Treatment Landscape, browse through our blog section
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
